compounded semaglutide or compounded tirzepatide fda bans and ban on The End of Semaglutide: Why the FDA's Decision Matters for is fda stopping compounded tirzepatide – What Sets Compounded Tirzepatide &

SN Compr Clin Med 3:10311041

Underwriters are also getting better at detecting GLP-1 use through: Prescription databases Medical records requests Follow-up health questionnaires What This Means for Your Clients If currently on GLP-1 medications: Expect questions about medication use and duration Be prepared for potentially higher rates despite current health improvements Consider timing of application if they've been stable on medication for an extended period If recently stopped GLP-1 medications: Underwriters may view recent discontinuation as a risk factor Weight regain could further complicate the application process Medical follow-up showing sustained health improvements may help If planning to start GLP-1 medications: Understand that future applications may be affected by medication use Industry Trends to Watch Some forward-thinking insurance companies are exploring partnerships with GLP-1 providers to improve medication adherence

Wash your hands and sit upright

If you take other drugs by mouth, you may need to take them at some other time than this drug

Additionally, another study showed participants who received a 15mg weekly dosage for 72 weeks experienced an average weight reduction of 22.5% of their starting body weight